Today's signal line

Follow the change, not the noise.

The day's most important shifts, ordered by time, source, and weight. Open a signal to see why it matters.

Bring the signals that matter to the top.

You're all caught up on today

Active Signal

FDA betting on Kalshi and Polymarket may corrupt drug trials

Source: New York Times
Time: 5:27 AM
Weight: 94/100High importance
How is it calculated?
A 0–100 editorial signal score. Higher scores carry more weight on the timeline.

Audio Brief

0:00 / 0:00

What happened?

The rise of prediction markets like Kalshi and Polymarket has introduced a new dynamic to the pharmaceutical industry, allowing users to bet on the outcomes of FDA drug approval decisions.

Why it matters

While these platforms are designed to provide crowdsourced forecasts, public health experts and regulators are raising concerns about the potential for such financial stakes to interfere with the integrity of clinical trials.

Original Source

Detailed explanation

The ability to profit from the success or failure of a treatment through speculative betting could create incentives that conflict with the objective goals of medical research.

Critics warn that these markets may encourage the manipulation of trial data or facilitate insider trading by individuals with access to non-public information.

There are also concerns that significant market activity could exert undue pressure on the FDA, potentially influencing the regulatory process or the timing of official announcements.

As recent legal rulings expand the scope of allowable betting markets in the United States, policymakers are debating whether additional safeguards are necessary to prevent speculative interests from compromising scientific rigor and public safety.

VOICE DISCUSSION / ASYNC0 voices

The voices around this story

Leave a thought in up to 60 seconds. Others can listen now or return later and continue the chain.

Tuning into the room…

Loading the timeline

Preparing the first signals.